Standout Papers

Acute Pain after Thoracic... 1996 2026 2006 2016 1996 200 400 600

Immediate Impact

6 by Nobel laureates 27 from Science/Nature 80 hit
Sub-graph 1 of 20

Citing Papers

Illusory generalizability of clinical prediction models
2024 HitScience
Probiotic-guided CAR-T cells for solid tumor targeting
2023 HitScience
3 intermediate papers

Works of Alan N. Sandler being referenced

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
2018
Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).
2015
and 1 more

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Alan N. Sandler 3.2k 2.2k 1.2k 869 790 108 5.6k
Marc De Kock 4.0k 1.2× 2.0k 0.9× 949 0.8× 402 0.5× 470 0.6× 146 6.2k
Donal J. Buggy 3.6k 1.1× 1.6k 0.7× 1.1k 0.9× 496 0.6× 342 0.4× 185 7.4k
Juan P. Cata 2.0k 0.6× 990 0.4× 638 0.5× 731 0.8× 303 0.4× 240 6.4k
Alain Borgeat 4.5k 1.4× 2.1k 0.9× 992 0.8× 228 0.3× 1.2k 1.5× 183 6.6k
Francis X. McGowan 1.9k 0.6× 1.5k 0.7× 2.0k 1.6× 1.3k 1.5× 390 0.5× 171 6.6k
Shung‐Tai Ho 2.2k 0.7× 1.2k 0.6× 444 0.4× 352 0.4× 393 0.5× 183 4.0k
Pierre Diemunsch 2.9k 0.9× 983 0.4× 872 0.7× 521 0.6× 186 0.2× 160 4.2k
Anthony D. Ivankovich 3.0k 1.0× 1.7k 0.8× 2.0k 1.6× 1.3k 1.5× 422 0.5× 154 5.8k
I. Murat 1.8k 0.6× 1.9k 0.9× 1.3k 1.1× 497 0.6× 133 0.2× 137 4.2k
Kenneth J. Tuman 3.1k 1.0× 1.6k 0.7× 1.6k 1.3× 675 0.8× 500 0.6× 128 4.9k

All Works

Loading papers...

Rankless by CCL
2026